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Synergistic effect of phosphodiesterase
4 inhibitor and serum on migration of
endotoxin-stimulated macrophages
Jing-Xing Yang1, Te-Chih Hsiung2, Fu-Chun Weng1,
Shiau-Li Ding1, Chin-Pyng Wu2, Marco Conti3,
Tsung-Hsien Chuang4 and S-L Catherine Jin1
Abstract
Macrophage migration is an essential step in host defense against infection and wound healing. Elevation of cAMP by
inhibiting phosphodiesterase 4 (PDE4), enzymes that specifically degrade cAMP, is known to suppress various inflam-
matory responses in activated macrophages, but the role of PDE4 in macrophage migration is poorly understood. Here
we show that the migration of Raw 264.7 macrophages stimulated with LPS was markedly and dose-dependently induced
by the PDE4 inhibitor rolipram as assessed by scratch wound healing assay. Additionally, this response required the
involvement of serum in the culture medium as serum starvation abrogated the effect. Further analysis revealed that
rolipram and serum exhibited synergistic effect on the migration, and the influence of serum was independent of PDE4
mRNA expression in LPS-stimulated macrophages. Moreover, the enhanced migration by rolipram was mediated by
activating cAMP/exchange proteins directly activated by cAMP (Epac) signaling, presumably via interaction with LPS/
TLR4 signaling with the participation of unknown serum components. These results suggest that PDE4 inhibitors,
together with serum components, may serve as positive regulators of macrophage recruitment for more efficient
pathogen clearance and wound repair.
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Introduction
Macrophages play key roles in innate immune
responses and wound repairing. To undertake these
functions, they must respond rapidly to wound or infec-
tion signals and migrate efficiently to sites of inflamma-
tion. While macrophage migration is critical to the
success of pathogen clearance and wound healing, inad-
equate regulation of this step may lead to progression of
a number of diseases, such as atherosclerosis, rheuma-
toid arthritis, and cancer.1 Therefore, a better under-
standing of the mechanisms underlying the control of
macrophage migration is crucial for the development of
therapies to treat these diseases.
Macrophages can be activated by numerous stimuli,
including the Gram-negative bacterial component LPS.
Through activation of TLR4, LPS potently stimulates
the production of various pro-inflammatory cytokines
and mediators, which in turn facilitate the recruitment
of neutrophils and monocytes, leading to local inflam-
mation. Additionally, LPS stimulation has also been
shown to induce migration of macrophages, enabling
the cells to clear infection and restore tissue homeosta-
sis.2–4 This LPS-mediated cell migration involves both
chemokinetic (random cell motility) and chemotactic
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(directional cell motility) activity, in which the lipid
mediators prostaglandin E2 (PGE2) and PGD2 and
the chemokine MCP-1, all secreted by LPS-stimulated
macrophages, are considered major regulators.2
The second messenger cAMP is known to regulate
diverse cellular processes. In immune cells, elevation of
cAMP generally leads to negative modulatory effects
on inflammatory responses, such as generation of pro-
inflammatory mediators, receptor-mediated phagocy-
tosis, and microbicidal ability.5 For instance, the
endogenous cAMP-elevating agent PGE2, cAMP ago-
nist 8-bromo-cAMP, and inhibitors of phosphodiester-
ase 4 (PDE4), a family of cAMP-hydrolyzing enzymes,
have been shown to suppress the production of many
pro-inflammatory mediators, such as TNF-a, IL-12,
CCL3, and leukotriene B4, while up-regulating the
anti-inflammatory cytokines IL-1Ra and IL-10 in
LPS-stimulated macrophages.5–8 Several studies also
point to a role of cAMP signaling in cell migration,
although conflicting effects are reported. Poole and
co-workers have revealed that by increasing cAMP,
PGE2 induces platelet-derived growth factor (PDGF)-
stimulated migration in murine IC21 macrophages
while inhibiting PDGF-stimulated fibroblast migra-
tion.9 This induction of macrophage migration by
PGE2/cAMP signaling is in line with the finding that
a late phase LPS-induced migration in Raw 264.7 mac-
rophages is mediated mainly by increasing secretion of
macrophage PGE2 and subsequent activation of the
cognate receptor EP4/cAMP signaling.2 Conversely,
the cAMP-elevating agent sphingosine 1-phosphate
(S1P) was found to inhibit C5a-induced migration in
bone marrow-derived macrophages.10 It is likely that
the effects of cAMP vary depending on the stimuli and
macrophage type under investigation.
The PDE4 isozymes are expressed in almost all
immune and inflammatory cells, implicating their
importance in regulation of intracellular cAMP level
and thereby, immune responses in these cells.11 By
increasing cAMP, presumably in discrete compartments
rather than global massive change in a cell,12,13 PDE4
inhibitors have been shown to suppress many inflamma-
tory responses in most inflammatory cells.6 In fact, the
PDE4 inhibitors roflumilast and apremilast are used as
anti-inflammatory drugs for the treatment of chronic
obstructive pulmonary disease and psoriasis and psori-
atic arthritis, respectively.14,15 Moreover, evidence also
indicates that inhibition of PDE4 generally suppresses
migration in both immune and non-immune cells. For
instance, PDE4 inhibitors have been shown to inhibit
epithelial cell migration in vivo during dextran sodium
sulfate-induced colonic damage,16 IL-1b- or nerve
growth factor-induced fibroblast migration,17,18 and
vascular endothelial growth factor-induced endothelial
cell migration.19,20 The PDE4 inhibitor rolipram has
also been documented to suppress the formation of
integrin-dependent actin adhesion microspikes and
impair the rate of random cell migration in rat embryo
fibroblasts.21 Additionally, eosinophil chemotaxis trig-
gered by eotaxin, platelet-activating factor, or leukotri-
ene B4,
22,23 and T lymphocyte trans-endothelial
migration induced by the chemokine CXCL12,24 are
all demonstrated to be inhibited by rolipram. These
findings clearly indicate an involvement of PDE4 in
cell migration.
Cell motility is a main characteristic of macrophages
and is essential for fulfilling most of their immune/
inflammatory effects. Although PDE4 inhibitors have
been shown to suppress migration of various types of
cells, the knowledge on the PDE4 regulation of macro-
phage migration is still lacking. Thus, in this study we
used murine Raw 264.7 macrophages to test whether
PDE4 plays a role in their migration. To our surprise,
inhibition of PDE4 greatly induced the migration of
LPS-stimulated macrophages when the cells were cul-
tured in the medium containing 10% serum. Further
analysis showed that this induction was the result of a
synergistic effect of PDE4 inhibitor and serum, since
rolipram or serum alone produced negligible or mini-
mal effect on migration. Moreover, this migration
induction is mediated by activation of cAMP/exchange
proteins directly activated by cAMP (Epac) signaling
but not cAMP/PKA pathway.
Materials and methods
Reagents
Escherichia coli LPS (O55:B5), 8-bromoadenosine
30,50-cyclic monophosphate (8-bromo-cAMP), 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT), Giemsa stain, rolipram, and roflumilast
were purchased from Sigma-Aldrich (St Louis, MO,
USA), murine monocyte chemoattractant protein-1
(MCP-1) is from PeproTech (Rocky Hill, NJ, USA),
and the Epac inhibitor ESI-09 and PKA inhibitor Rp-
8-CPT-cAMPS were from BioLog Life Science
Institute (Bremen, Germany). The DMEM medium
base, FBS, and horse serum were obtained from
Thermo Fisher Scientific (Waltham, MA, USA).
Cell line
Raw 264.7, a murine leukemia macrophage, cell line
was obtained from Bioresource Collection and
Research Center (Hsinchu City, Taiwan). The cells
were maintained in DMEM medium supplemented
with 100 u/ml penicillin, 100 mg/ml streptomycin, and
10% FBS at 37C in 5% CO2. For scratch wound
healing assay, cells were plated at 2.5 105 or
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1.2 105 cells/well in 24- or 48-well plate, respectively,
grown overnight, and then the wound was created fol-
lowed by LPS and drug treatment. For quantitative
PCR analysis of PDE4 mRNA expression, the cells
were plated at 2 106 cells/well in 6-well plate, cultured
to 80–90% confluency, and then treated with 0.1 mg/ml
LPS for 3 and 12 h in serum-free or 10% FBS-
containing medium.
Scratch wound healing assay
Raw 264.7 cells were grown until they had reached
about 80% confluence. Then a wound was created in
the cell monolayer by scratching a vertical line at the
center of each well using a sterile 200-ml pipette tip.
Cells were washed twice with PBS to remove debris,
followed by incubation with 0.1 mg/ml LPS in the
absence or presence of PDE4 inhibitors or cAMP ana-
logs in serum-free or serum-containing medium. The
wound area was photographed at time 0 and desig-
nated incubation times under a light microscope (mag-
nification 40, Coolpix 4500, Nikon, Tokyo, Japan).
Pictures of each well were taken exactly at the same
position before and after the treatment to verify the
healing process. Cells migrated off the scratch edges
toward the wound area were counted using ImageJ
1.47v software. All experiments were performed at
least in duplicate wells and repeated more than
five times.
Cell viability assay
Raw 264.7 cells were plated in 96-well plate, cultured
overnight, followed by incubation for 24 h under the
conditions corresponding to those conducted in the
wound healing assay, and then cell viability was deter-
mined by adding MTT solution (at the final concentra-
tion of 0.5 mg/ml). Following 3 h incubation at 37C in
5% CO2, the medium was removed and 200 ll DMSO
added to dissolve the insoluble formazan formed in the
cells. Then the absorbance at 570 nm was measured
using a microplate reader (VersaMax, Molecular
Devices, San Jose, CA, USA). Cell viability was
expressed as percent survival of untreated cells.
Transwell migration assay
To determine whether PDE4 inhibition affects LPS-
and the chemokine MCP-1-mediated chemotactic
migration, a modified Boyden chamber assay was car-
ried out in 24-well plates with 8-lm pore-size polycar-
bonate membrane (Corning, NY, USA) in DMEM
medium supplemented with 2% FBS. Following pre-
treatment of Raw 264.7 cells with 10 lM rolipram or
vehicle for 20 min, 5 105 cells in 200 ll of the medium
were seeded in the upper chamber, and increasing
concentrations of LPS or 20 ng/ml recombinant
murine MCP-1 in 600 ll medium were added in the
lower chamber. After 4 h incubation at 37C, the
cells remained on the upper side of the membrane
were wiped off with a cotton swab and the migrating
cells on the underside of the membrane were fixed with
10% formalin in PBS for 10 min. The cells then were
stained with 5% Giemsa stain for 40min followed by
washing with water. The cells were counted in four
randomly selected fields by light microscopy at 200
magnification.
RNA isolation, cDNA synthesis, and quantitative PCR
Total RNA was extracted from Raw 264.7 cells with
the TRIzol reagent (Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s
protocol. First strand cDNA was synthesized from 1 mg
of total RNA in the presence of random primer using
M-MLV reverse transcriptase according to the manu-
facturer’s instruction (Thermo Fisher Scientific,
Waltham, MA, USA). Real-time PCR was carried
out with the SensiFAST SYBR Hi-ROX kit (Bioline,
London, UK) using Applied Biosystems Prism 7900
Real-time PCR Detection System (Applied
Biosystems, CA, USA). The reaction was performed
in a 10 ml reaction mixture with preliminary denature
for 10 min at 95C, followed by 40 cycles of denaturing
at 95C for 30 s, annealing at 60C for 30 s, and exten-
sion at 72C for 30 s. Oligonucleotide primer sequences
were as follows: PDE4A, 50-CTTCTGCGA
GACCTGCTCCA-30 and 50-GAGTTCCCGGTT
CAGCATCC-30; PDE4B, 50-GCCACTGGATGAG
AGGAGCA-30 and 50-CCTTTTCCGGTCCCT
CAGAA-30; PDE4C, 50-CTCTGCCCACAGACT
GGAAT-30 and 50-ACAGAGTCCGACTGCA
TGTG-30; PDE4D, 50-ACCGCCAGTGGACGGACC
GGA-30 and 50-CATGCCACGCTCCCGCTCTCGG-
30; MIF, 50-GCCAGAGGGGTTTCTGTCG-30 and
50-GTTCGTGCCGCTAAAAGTCA-30; GAPDH,
50-GGAGCGAGACCCCACTAACA-30 and 50-ACA
TACTCAGCACCGGCCTC-30. All primers used
were synthesized by Tri-I Biotech (New Taipei City,
Taiwan). Target gene expression was calculated by
the comparative DD cycle threshold (Ct) method for
relative quantification after normalization to the house-
keeping gene GAPDH expression.
Statistical analysis
All data are presented as mean SEM of at least three
independent experiments. Comparisons of two treat-
ment groups were performed by unpaired Student’s
t-test. Most data also were analyzed using Mann-
Whitney/Wilcoxon rank sum test (for sample size  4)
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to confirm the statistical significance. Values were con-
sidered statistically significant when P< 0.05.
Results
PDE4 inhibitor enhances cell migration in
LPS-stimulated Raw 264.7 macrophages
To investigate whether PDE4 regulates macrophage
migration, scratch wound healing assay was performed
in Raw 264.7 macrophages incubated with LPS in the
presence or absence of the PDE4 inhibitor rolipram.
The initial microscopic examination revealed that
LPS treatment for 24 h led to an increasing number
of cells migrating off the scratch edges toward the
center of the wound area as compared with the basal
migration of untreated cells. Surprisingly, the migra-
tion activity was markedly enhanced when the cells
were co-treated with rolipram, while rolipram alone
had no significant effect (Figure 1a). Counting migra-
tion cells using ImageJ software revealed that there was
a time-dependent increase in migration activity up to
24 h for all test conditions (Figure 1b). When compared
with the untreated cells, LPS mildly, but significantly,
increased cell migration during the 4-24 h incubation
period (P< 0.05), a result consistent with other reports
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Figure 1. PDE4 inhibitor enhances migration of LPS-stimulated macrophages. Raw 264.7 macrophages were pre-treated with 10 mM
rolipram (Rol) or vehicle for 20 min followed by stimulation with or without 0.1 mg/ml LPS for 24 h. Cell migration was measured by
scratch wound healing assay. (a) Images taken at 0 and 24 h are shown (40 magnification). Representative of at least five experiments.
(b) Cells migrated into the wound area at the indicated times were counted using ImageJ software. (c) Migration cell numbers counted
at 24 h in (b) are presented as bar graphs. (d) The cell viability at 24 h was determined by MTT assay. Data are the mean SEM (b,
n¼ 6–9; c, n¼ 9; d, n¼ 6). *P< 0.001, compared with untreated cell; **P< 0.001, compared with the cells treated with LPS alone.
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using a modified Boyden chamber assay.2–4 The LPS-
stimulated migration was escalated by rolipram after
12 h incubation (P< 0.001), showing approximately
1.7- and 2.0-fold increase at 16 and 24 h, respectively
(Figure 1b and c). This enhanced chemokinetic migra-
tion was not caused by an increase in cell viability as no
significant difference in cell survival was detected
among the four test conditions (Figure 1d).
To further confirm the rolipram effect on macro-
phage migration, Raw 264.7 cells were incubated with
LPS in the presence of increasing concentrations of
rolipram for 24 h. Figure 2a shows that rolipram
enhances the cell migration in a concentration-
dependent manner. A similar dose response also was
obtained when the cells were treated with the cAMP
agonist 8-bromo-cAMP (Figure 2b). Moreover, the
clinically used PDE4 inhibitor roflumilast was found
to recapitulate the migration effect of rolipram
(Figure 2c). These results suggest that Raw 264.7 cell
migration enhanced by PDE4 inhibitors is mediated by
activating cAMP signaling.
To further determine whether PDE4 inhibition also
increases directional migration in macrophages in
response to LPS as well as to the chemotactic mediator
MCP-1, a modified Boyden chamber migration assay
was performed. As shown in Figure 3a, migration of
Raw 264.7 cells through the transwell membrane was
increased in a LPS-dose-dependent manner, and the
migration activity at 10 and 100 ng/ml LPS were sig-
nificantly enhanced when the cells were pre-treated
with rolipram for 20 min (P< 0.01 and 0.005, respec-
tively). However, rolipram alone had no significant
effect on the migration (Figure 3b). As expected, the
cell motility was increased when the chemokine MCP-1
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Figure 2. cAMP-elevating agents dose-dependently enhance cell migration in LPS-stimulated macrophages. Raw 264.7 cells were pre-
treated with increasing concentrations of rolipram (a) or 8-brome-cAMP (b) for 20 min, followed by stimulation with 0.1 mg/ml LPS for
24 h. (c) Cells were treated with 1 mM roflumilast (Rof) or vehicle for 20 min before stimulation with or without 0.1 mg/ml LPS for 24
h. Cell migration was monitored and measured as described in Figure 1. Data are the mean SEM (a, n¼ 6–8; b, n¼ 4–5; c, n¼ 3–4).
*P< 0.05, compared with untreated cell; **P< 0.001, compared with the cells treated with LPS alone.
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Figure 3. PDE4 inhibitor enhances directional migration of macrophages in response to LPS but not to MCP-1. In vitro chemotactic
migration of Raw 264.7 cells was measured by a modified Boyden transwell chamber assay. The cells were pre-treated with 10 mM
rolipram (Rol) or vehicle for 20 min and then placed in the upper chamber of a transwell. The lower chamber contained either
increasing concentrations of LPS (a), 0.1 mg/ml LPS (b), or 20 ng/ml MCP-1 (c). After 4 h incubation, migration was quantified as
described under “Materials and methods.” Data are the mean SEM (n¼ 6). *P< 0.01, **P< 0.005, compared with cells treated with
LPS alone; ***P< 0.001, compared with untreated cells.
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was added to the lower chamber of the transwell, yet
the migration activity was unaffected by rolipram
pretreatment (Figure 3c). Taken together, these data
indicate that inhibition of PDE4 selectively enhances
LPS-mediated chemotactic migration in macrophages.
The rolipram-enhanced migration in LPS-stimulated
macrophages requires the involvement of serum
Several studies have shown that serum promotes cell
migration in various cell types, such as epithelial cells,
fibroblasts, and cancer cells.25–27 Given the fact that
our data presented in Figures 1 and 2 were obtained
from the cells incubated in 10% FBS-containing
medium, the literature reports prompted us to examine
whether serum also contributes to the rolipram
enhancement of macrophage migration. To this pur-
pose, Raw 264.7 cells were treated with LPS with or
without rolipram in the serum-free medium for 24 h.
As shown in Figure 4a, a time-dependent increase in
cell migration was obtained under all four test condi-
tions albeit the migration reached a plateau after 16 h
in the cells treated with LPS alone or LPS plus roli-
pram. Compared with Figure 1b and c, there were less
migration cells detected under serum starved condi-
tions (Figure 4a and b). Additionally, it was obvious
that rolipram had no effect on cell migration since cell
treatment with rolipram alone or LPS plus rolipram
displayed no significant difference in migration from
their control groups (Figure 4a and b). This lack of
increase in cell migration was not caused by a decrease
in cell viability as no significant difference in cell sur-
vival was detected among the four conditions
(Figure 4c). These data indicate that serum is required
for the observed rolipram effect in macrophage migra-
tion under LPS stimulation.
Rolipram and serum exhibited synergistic effect on
migration of LPS-stimulated macrophages
To further investigate whether the enhanced macro-
phage migration by PDE4 inhibitors is serum concen-
tration dependent, Raw 264.7 cells were incubated in
the medium containing 0, 2, or 10% FBS and the cell
migration was evaluated in the absence or presence of
LPS or rolipram. The results showed that the migration
of untreated cells (Figure 5a) and the cells treated with
rolipram alone (Figure 5b) or LPS alone (Figure 5c)
was significantly increased at 24 h in 2% FBS medium
(P< 0.01), while the increase was either reduced
(Figure 5a and b) or only marginally increased
(Figure 5c) in 10% FBS medium. However, a serum
dose-dependent increase in migration was detected in
cells treated with LPS plus rolipram (Figure 5d), sug-
gesting that serum constituents specifically up-regulate
the rolipram effect on macrophage migration under
LPS stimulation. Moreover, we also observed that
cells treated with LPS alone without an influence of
serum exhibited a trend of decrease in cell migration
(0% FBS in Figure 5c), while rolipram alone showed a
negligible or minimal increase in migration (0% FBS in
Figure 5B) as compared with the cell migration in
untreated cells (0% FBS in Figure 5a). Since 10%
serum alone (Figure 5a) and rolipram alone without
serum (Figure 5b) produced limited effect on cell
migration, the substantial increase in migration cell
number under the condition of LPS plus rolipram in
10% serum (Figure 5d) indicates a synergistic effect of
rolipram and serum on the migration of
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Figure 4. Rolipram enhancement of cell migration in LPS-stimulated macrophages is abrogated in serum-free condition. Raw 264.7
cells incubated in the serum-free medium were treated with 10 mM rolipram or vehicle for 20 min, followed by stimulation with or
without 0.1 mg/ml LPS for 24 h. (a) Cells migrated into the wound area at the indicated times were counted using ImageJ software.
(b) Migration cell numbers counted at 24 h in (A) are presented as bar graphs. (c) The cell viability at 24 h was determined by MTT
assay. Data are the mean SEM (a and b, n¼ 10; c, n¼ 6). *P< 0.01, **P< 0.005, cells treated with LPS alone compared with
untreated cells.
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LPS-stimulated cells. Further MTT assay revealed that
this synergistic induction in migration was not caused
by an increase in cell viability as comparable cell sur-
vival was detected under the conditions of 2% FBS and
10% FBS medium (Figure 5e to h).
To assess whether sera from other animal sources
also produce the same migration effect as FBS,
mouse and horse sera were tested. The results showed
that similar pattern and levels of migration induced by
LPS and rolipram were detected at 24 h in 10% mouse
serum (migration cell numbers: none, 399 32; Rol,
438 40; LPS, 599 44; LPSþRol, 1091 86; n¼ 4)
as well as in 10% horse serum (migration cell numbers:
none, 287 22; Rol, 315 31; LPS, 530 80; LPSþ
Rol, 1020 132; n¼ 5). These data indicate the pres-
ence of common factor(s) in the sera that is (are)
necessary for the rolipram enhancement of macrophage
migration.
Serum does not alter PDE4 expression in
LPS-stimulated macrophages
To test whether serum influences PDE4 expression and
thereby contributes to the observed migration effect in
LPS-stimulated macrophages, Raw 264.7 cells were
incubated with LPS in the presence or absence of roli-
pram in 0% and 10% FBS-containing medium for 3
and 12 h. The mRNA levels of the four PDE4 isoforms
(PDE4AD) were measured by quantitative PCR. As
expected, PDE4C expression was undetectable or at
low levels (data not shown).6 As depicted in Figure 6,
PDE4D was the predominant isoform expressed in the
control cells cultured in both media at both incubation
times. Following stimulation with LPS alone, the
expression profiles of the three PDE4 isoforms under
serum-free and 10%-serum conditions were compara-
ble, with PDE4B expression being upregulated the
greatest at 3 h incubation (approximately 31- and 22-
fold increase, respectively) and then declined at 12 h
(approximately 7- and 8-fold increase, respectively),
and no induction detected with PDE4A and PDE4D
expression (Figure 6). These results indicate that serum
has no major effect on PDE4 mRNA expression in
LPS-stimulated macrophages.
The PDE4 expression profiles in Raw 264.7 cells
treated with rolipram alone and LPS plus rolipram
were also evaluated. Previous studies by us and
others have revealed that in addition to LPS, cAMP
also induces PDE4B expression in monocytes and mac-
rophages, and this expression is synergistically up-
regulated by cAMP and LPS.28,29 Indeed, as shown
in Figure 6, by elevating cAMP, rolipram elicited a
marked increase in PDE4B expression when the cells
were co-treated with LPS. Additionally, the expression
profiles of PDE4 isoforms were comparable under
serum-free and 10%-serum conditions at both incuba-
tion times. However, it is worthy of note that the pro-
found increase in the PDE4B expression under the
condition of LPS plus rolipram would have no func-
tional impact, simply because the presence of 10 lM
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Figure 5. Rolipram-enhanced cell migration in LPS-stimulated macrophages is serum concentration dependent. Raw 264.7 cells
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rolipram would inhibit almost all PDE4 enzymatic
activity and therefore is regarded as no functional
PDE4 in the cell. Taken together, these data clearly
indicate that the serum effect on the macrophage
migration is independent of PDE4 expression in
these cells.
Rolipram and serum enhanced migration in
LPS-stimulated macrophages is mediated by
activating cAMP-Epac signaling
To further assess which cAMP effector pathway medi-
ates the migration effect of rolipram and serum, Raw
264.7 cells cultured in the 10% FBS-containing
medium were treated with LPS in the absence or pres-
ence of the PKA inhibitor Rp-8-CPT-cAMPS or the
Epac inhibitor ESI-09 for 24 h. Figure 7a shows that
the rolipram-enhanced cell migration was dose-
dependently inhibited by ESI-09, and a full inhibition
was obtained at 10 lM ESI-09. Contrarily, PKA inhib-
itor had minimal or no impact on the cell migration
(Figure 7b). These results indicate that the rolipram
enhancement of macrophage migration is mediated
by activation of cAMP/Epac but not cAMP/PKA
signal pathway.
Discussion
The main goal of this study was to investigate whether
PDE4 modulates macrophage migration under LPS
stimulation. Using murine Raw 264.7 macrophages
cultured in 10% serum-containing medium, we show
that LPS mildly, but significantly, induces macrophage
migration as assessed by scratch wound healing assay
and this effect is greatly enhanced by the PDE4 inhib-
itors rolipram and roflumilast. We further demonstrate
that this migration induction by PDE4 inhibitor
requires the involvement of serum in the medium,
whereas the PDE4 inhibitor or serum alone has negli-
gible or minimal effect. Moreover, this enhanced
migration is mediated by activation of cAMP-
Epac signaling.
In addition to the scratch wound healing assay to
assess chemokinetic migration, we also performed a
transwell migration assay to evaluate directional motil-
ity in macrophages. Our data show that LPS signifi-
cantly induces directional motility of macrophages
(Figure 3), a result consistent with other reports.2–4
Additionally, this LPS-induced migration is further
enhanced by rolipram, indicating that inhibition of
PDE4 promotes both chemokinetic and chemotactic
activity of LPS-mediated migration in macrophages.
Conversely, the directional migration mediated by the
18
15
12
9
6
3
0
PDE4A PDE4B PDE4D PDE4A PDE4B PDE4D
PDE4A PDE4B PDE4DPDE4A PDE4B PDE4D
10
8
6
4
2
0
10
8
6
4
2
0
25 None
Rol
LPS
LPS+Rol
None
Rol
LPS
LPS+Rol
None
Rol
LPS
LPS+Rol
None
0% serum (3 h) 0% serum (12 h)
10% serum (12 h)10% serum (3 h)
Rol
LPS
LPS+Rol
PD
E4
 m
R
N
A 
le
ve
l
(fo
ld 
ch
an
ge
)
PD
E4
 m
R
N
A 
le
ve
l
(fo
ld 
ch
an
ge
)
PD
E4
 m
R
N
A 
le
ve
l
(fo
ld 
ch
an
ge
)
PD
E4
 m
R
N
A 
le
ve
l
(fo
ld 
ch
an
ge
) 20
15
10
5
0
Figure 6. Serum does not alter PDE4 isoform expression in LPS-stimulated macrophages. Raw 264.7 cells incubated in the medium
containing 0% or 10% FBS were treated with 10 mM rolipram or vehicle for 20 min, followed by stimulation with or without 0.1 mg/ml
LPS for 3 and 12 h. The mRNA levels of PDE4A, PDE4B, and PDE4D in the cells were measured by real-time PCR and normalized to
GAPDH mRNA levels. Data are presented as fold change compared with the PDE4A mRNA level at 3 h in the control cells cultured in
the serum-free medium. Data are the mean SEM (n¼ 5–6).
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chemokine MCP-1 is not affected by rolipram, suggest-
ing that PDE4 inhibitor, hence cAMP signaling, selec-
tively regulates LPS-mediated chemotaxis in
macrophages.
FBS is a well-known stimulant for cell migration.30
It contains a wide variety of growth factors, such as
PDGF, fibroblast growth factor, TGF, and insulin-like
growth factor (IGF). These factors promote not only
the fibroblast and cancer cell motility, but also macro-
phage migration.31–33 By supplementing FBS in the
incubation medium, we observed significant increases
in macrophage migration under the basal (no drug
treatment) condition (Figure 5a), in which the increase
is more pronounced in 2% than in 10% FBS medium
(2%, P< 0.01; 10%, P< 0.05, compared with the 0%
control). This finding is consistent with the previous
report on fibroblasts, where the migration speed of
fibroblasts measured in the presence of increasing con-
centrations of FBS reaches the highest at 2% FBS and
then trends toward the baseline migration when FBS
concentration increases up to 20%.30 Compared with
the untreated cells (Figure 5a), the cells treated with
rolipram alone displayed similar pattern and levels of
increase in migration at both 2% and 10% FBS con-
centrations (Figure 5b), indicating rolipram itself has
limited impact on macrophage migration. The serum
effect on the basal migration probably is instigated by a
combined effect of several serum factors. A study by
Furundzija et al. has shown that the serum factor IGF-
1 is chemotactic to macrophages and its effect on
migration induction involves activation of integrins
and focal adhesion formation via inside-out 3-kinase/
PKC/p38-dependent signaling.33 Additionally, Krettek
et al. found that the homodimer of PDGF B chain
(PDGF-BB) also stimulates the migration of macro-
phages, with an increase primarily in random motility
(chemokinesis).31 However, TGF-b1 was shown to
stimulate macrophage migration only in the early
phase of the treatment because an inhibitory effect
was detected during the late phase.32
In LPS-stimulated macrophages, we observed a mild
but consistent decrease in migration cell number under
serum-free and 2% serum conditions (Figure 5c) as
compared with the untreated cells (Figure 5a).
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Figure 7. Rolipram and serum induced migration in LPS-stimulated macrophages is mediated by activation of Epac. Raw 264.7 cells
were pre-treated with 10 mM rolipram, increasing concentrations of the Epac inhibitor ESI-09 in the presence or absence of rolipram
(a) or the PKA inhibitor Rp-8-CPT-cAMPS (500 mM) or a combination of rolipram and Rp-8-CPT-cAMPS (b) for 20 min prior to LPS
stimulation for 24 h. Cell migration was assessed as described in Figure 1. Data are the mean SEM (a, n¼ 4–8; b, n¼ 3–6). *P< 0.05,
compared with untreated cell; **P< 0.01, ***P< 0.001, compared with the cells treated with LPS alone.
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However, these cells displayed a marginal but signifi-
cant increase in migration when the serum concentra-
tion increased from 2% to 10% (P< 0.05, Figure 5c),
showing a positive impact of serum on migration in
LPS-treated cells. Additionally, the migration of LPS-
stimulated macrophages was greatly induced by 10%
serum when the cells were co-treated with rolipram (ca.
2.5-fold increase compared with the cells treated with
2% serum; Figure 5d), suggesting PDE4 negatively reg-
ulates macrophage migration when the cells are under a
combined stimulation of LPS and serum component(s).
From these results, we propose that with the participa-
tion of unknown serum factor(s), LPS/TLR4-elicited
signaling might crosstalk to the cAMP signaling acti-
vated by PDE4 inhibitors, from which cell migration
is escalated.
In addition to the growth factors, LPS-binding pro-
tein (LBP), a protein found in abundance in serum, is
also likely to be a critical factor for the rolipram-
enhanced migration in LPS-stimulated Raw 264.7
cells. It is well established that by initiating pro-
inflammatory responses during infection and inflam-
mation, LPS is recognized by LBP and then transferred
to CD14 receptor and subsequently to the MD2/TLR4
complex on inflammatory cell surface.34 Evidence indi-
cates that in the presence of serum, cells that possess
surface CD14 display an increased sensitivity to LPS by
100 to 1000 folds, and this increased sensitivity is medi-
ated by LBP.35,36 Additionally, unlike Kupffer cells
and most intestinal macrophages that lack or express
low level of CD14 receptor, Raw 264.7 cells, a perito-
neal macrophage cell line, are abundant in surface
CD14.37,38 On the basis of these findings, we postulate
that LBP, and thereby the formation of LPS/LBP com-
plex, is essential for the binding of LPS to CD14 and
then to MD2 in Raw 264.7 cells. The binding of LPS
and MD2 initiates the formation of MD2/TLR4 com-
plex which then activates the MyD88 (myeloid differ-
entiation factor)-dependent and -independent
pathways, leading to the induction of cell migration
(LPS-induced migration). When PDE4 inhibitor is pre-
sent, the elicited cAMP/Epac signaling interacts with
the LPS/TLR4 signaling resulting in further increase in
cell migration (PDE4 inhibitor-enhanced migration).
This proposed essential role of LBP in macrophage
migration explains why the migration activity induced
in LPS and LPSþRol treated cells is abrogated
when serum is absent (Figures 4b and 5c and d).
Nevertheless, further experiments are necessary to
verify whether LBP is essential for activating down-
stream LPS/TLR4 signaling and cell migra-
tion regulation.
Macrophage migration inhibitory factor (MIF), a
cytokine released by inflammatory cells, is known to
inhibit monocyte/macrophage migration.39 A study
by Calandra et al. has shown that low dose LPS (<1
mg/ml) stimulates MIF release in Raw 264.7 cells.40 To
determine whether the rolipram-enhanced migration is
associated with a decrease in MIF expression, we also
quantified MIF mRNA levels in Raw 264.7 cells and
found there was a significant increase (P< 0.05) in MIF
mRNA expression in the cells treated with LPS for 3 h,
but the mRNA level was not affected by co-treatment
with rolipram (data not shown).
Figure 2 shows that the cAMP-elevating agents roli-
pram and 8-bromo-cAMP dose-dependently increase
migration in LPS-stimulated macrophages. This
cAMP effect is consistent with the reports of other
groups, where macrophage migration is induced by
PGE2 through activation of EP2 and/or EP4 receptors
to promote cAMP production.2,9,41 These results also
are in line with the finding that roflumilast treatment of
COPD patients induces, rather than suppresses, phago-
cytic activity of peripheral blood cells, which results in
an improvement of lung function.42 On the contrary,
increasing cAMP has also been shown to inhibit mac-
rophage migration. Moon et al. found that elevation of
cAMP by long-term (24 h) treatment of Raw 264.7 cells
with TGF-b1 activates sequentially Epac, Rap1, and
ARAP3 (Rap-dependent RhoGAP), resulting in sup-
pression of RhoA activity and then macrophage migra-
tion.43 A study by Michaud et al. also showed that
activation of S1P receptor 2 in macrophages induces
cAMP production while inhibits Akt phosphorylation,
which leads to a decrease in C5a-induced chemotaxis.10
The reason for the opposite effects of cAMP on migra-
tion is unknown, but could possibly be due to different
stimulation conditions and types of macrophage
being used.
Cyclic cAMP regulation of immune cell functions
generally is mediated by activating its effector protein
PKA or Epac.5 Here we demonstrate that Epac, but
not PKA, is involved in the rolipram/serum-enhanced
migration in LPS-stimulated macrophages. This result
coincides with the finding that the synthetic Epac acti-
vator promotes migration of smooth muscle cells in rat
ductus arteriosus.44 Conversely, cAMP-Epac signaling
has been shown to inhibit migration of various cell
types, such as human prostate carcinoma cells,45
PDGF-treated human vascular smooth muscle cells,46
and human pancreatic ductal adenocarcinoma cells.47
The reason for the contradictory results is unknown,
possibly due to cell type and species differences.
LPS-elicited macrophage migration can be
explained by several mechanisms. LPS is known to
activate macrophages via TLR4,48 from which the pro-
duction of immunomodulatory factors is evoked. The
production of MCP-1, a chemokine known to regulate
the migration and infiltration of monocytes/macro-
phages, is induced by LPS,49 via activation of the
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LPS/TLR4/MyD88/NF-jB signaling pathway.48
However, the MCP-1induced migration is not further
enhanced by rolipram, as indicated in Figure 3c.
A study by Tajima et al. has demonstrated that LPS
stimulation of macrophage triggers secretion of PGD2
and PGE2, two lipid inflammatory mediators, through
which the receptor signaling of CRTH2 and EP4,
respectively, are activated to promote LPS-mediated
migration.2 Additionally, LPS has been shown to stim-
ulate reactive oxygen species (ROS) production in Raw
264.7 cells through activation of the ERK1/2 signal
pathway, which in turn promotes MMP-9 expression
and cell migration.3 A following study by Yang et al.
has shown that TLR4/NF-jB signaling is required for
LPS-induced MMP9 expression and cell migration in
Raw 264.7 cells.4 Further studies are necessary to elu-
cidate which pathway is modulated by PDE4/
cAMP signaling.
In summary, our data demonstrate that with the
involvement of serum constituents, the migration of
LPS-stimulated macrophages is markedly enhanced
by PDE4 inhibition. The enhancement of migration is
mediated by activation of cAMP/Epac signaling, pre-
sumably via interaction with LPS/TLR4 signaling with
the participation of unknown serum factors. While it is
not clear as yet whether the anti-inflammatory effects
of PDE4 inhibitors have input to macrophage migra-
tion, here the observed rolipram effect on migration
may imply a more efficient clearance of infection and
thereby wound repair by this family of cAMP-
elevating agents.
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